Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 3:1
Drug Approvals
14
CANADA:6
FDA:2
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 3
1 (100.0%)Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients with Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)
Phase 3
Recruiting
- Conditions
- Bladder CancerNeoplasm RecurrenceNon-Invasive Bladder Urothelial CarcinomaBladder Cancer RecurrentUrothelial Carcinoma BladderUrothelial Carcinoma Recurrent
- First Posted Date
- 2021-09-08
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Verity Pharmaceuticals Inc.
- Target Recruit Count
- 540
- Registration Number
- NCT05037279
- Locations
- 🇨🇦
Site 05, Vancouver, British Columbia, Canada
🇨🇦Site 04, Kingston, Ontario, Canada
🇨🇦Site 01, Toronto, Ontario, Canada
News
No news found